| Name | Title | Contact Details |
|---|
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
Oncology Therapeutics Network is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Secura Bio™ is a pharmaceutical company committed to giving patients access to innovative therapies. Headquartered in Henderson, Nevada, Secura Bio™ has operations in the U.S. and Offices in San Diego.
HNP Pharmaceuticals is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners.